Venom Biologics Overview
- Status
-
Private
- Latest Deal Type
-
Accelerator/Inc
- Latest Deal Amount
-
$30K
- Investors
-
1
Venom Biologics General Information
Description
Developer of non-opioid chronic pain treatments designed for targeted ion channel modulation. The company offers non-opioid analgesics, engineered venom peptides, chronic pain treatments, NaV1.8 inhibitors, peripheral pain modulators, and peptide-based therapeutics, enabling chronic pain patients to manage symptoms through engineered peptides derived from scorpion venom.
Contact Information
Corporate Office
- Dallas, TX
- United States
Corporate Office
- Dallas, TX
- United States
Venom Biologics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Accelerator/Incubator | 10-Sep-2026 | $30K | Completed | Startup |
Venom Biologics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Health Wildcatters | Accelerator/Incubator | Minority |
Venom Biologics FAQs
-
Where is Venom Biologics headquartered?
Venom Biologics is headquartered in Dallas, TX.
-
What industry is Venom Biologics in?
Venom Biologics’s primary industry is Drug Discovery.
-
Is Venom Biologics a private or public company?
Venom Biologics is a Private company.
-
What is the current valuation of Venom Biologics?
The current valuation of Venom Biologics is .
-
What is Venom Biologics’s current revenue?
The current revenue for Venom Biologics is .
-
How much funding has Venom Biologics raised over time?
Venom Biologics has raised $30K.
-
Who are Venom Biologics’s investors?
Health Wildcatters has invested in Venom Biologics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process